Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhou, Ying | - |
dc.contributor.author | Maiti, Mrinmoy | - |
dc.contributor.author | Sharma, Amit | - |
dc.contributor.author | Won, Miae | - |
dc.contributor.author | Yu, Le | - |
dc.contributor.author | Miao, Lan Xi | - |
dc.contributor.author | Shin, Jinwoo | - |
dc.contributor.author | Podder, Arup | - |
dc.contributor.author | Bobba, Kondapa Naidu | - |
dc.contributor.author | Han, Jiyou | - |
dc.contributor.author | Bhuniya, Sankarprasad | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-09-02T05:01:20Z | - |
dc.date.available | 2021-09-02T05:01:20Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-10-28 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/72434 | - |
dc.description.abstract | We report herein, an azo-derivative (AzP1) of FDA approved antineoplastic drug SN-38 (irinotecan analogue) as a theranostic agent with a potential for both tumor hypoxia-specific activation and therapy. The theranostic AzP1 was found to be stable within a biologically relevant pH scale and was chemically inert towards other competitive biological analytes. However, upon treatment with rat-liver microsomes, AzP1 showed a self-calibrated fluorescence enhancement at lambda(em) = 560 nm. The cytotoxicity profile of AzP1 was tested in various cancer lines. Under hypoxic conditions, prodrug AzP1 exhibited activation to release the parent drug (SN-38) and enhanced cytotoxicity in cancer cells with concomitant fluorescence enhancement at 560 nm, which served to monitor both the drug activation and tracing purposes. The therapeutic potential of AzP1 for both tumor-specific activation and suppression of tumor weights was validated in xenograft mouse model. Collectively, the synthetic ease and hypoxia-sensitive activation along with promising therapeutic properties highlight the potential of theranostic AzPI in future cancer treatment programs. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | IN-VIVO | - |
dc.subject | FLUORESCENT-PROBE | - |
dc.subject | PRODRUG | - |
dc.subject | CELLS | - |
dc.subject | DRUG | - |
dc.subject | ACTIVATION | - |
dc.subject | LUMINOGEN | - |
dc.subject | RECEPTOR | - |
dc.subject | GROWTH | - |
dc.title | Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Won, Miae | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1016/j.jconrel.2018.08.036 | - |
dc.identifier.scopusid | 2-s2.0-85052658395 | - |
dc.identifier.wosid | 000446237700002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.288, pp.14 - 22 | - |
dc.relation.isPartOf | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 288 | - |
dc.citation.startPage | 14 | - |
dc.citation.endPage | 22 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | FLUORESCENT-PROBE | - |
dc.subject.keywordPlus | PRODRUG | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | LUMINOGEN | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | GROWTH | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.